Abstract | PURPOSE OF REVIEW: To summarize current knowledge and provide perspective on relationships between human genetic variants, antiretroviral medications, and aging-related complications of HIV-1 infection. RECENT FINDINGS: Human genetic variants have been convincingly associated with interindividual variability in antiretroviral toxicities, drug disposition, and aging-associated complications in HIV-1 infection. Screening for HLA-B5701 to avoid abacavir hypersensitivity reactions has become a routine part of clinical care, and has markedly improved drug safety. There are well established pharmacogenetic associations with other agents ( efavirenz, nevirapine, atazanavir, dolutegravir, and others), but this knowledge has yet to have substantial impact on HIV-1 clinical care. As metabolic complications including diabetes mellitus, dyslipidemia, osteoporosis, and cardiovascular disease are becoming an increasing concern among individuals who are aging with well controlled HIV-1 infection, human genetic variants that predispose to these complications also become more relevant in this population. SUMMARY: Pharmacogenetic knowledge has already had considerable impact on antiretroviral prescribing. With continued advances in the field of human genomics, the impact of pharmacogenomics on HIV-1 clinical care and research is likely to continue to grow in importance and scope.
|
Authors | David W Haas, Philip E Tarr |
Journal | Current opinion in HIV and AIDS
(Curr Opin HIV AIDS)
Vol. 10
Issue 2
Pg. 116-22
(Mar 2015)
ISSN: 1746-6318 [Electronic] United States |
PMID | 25565175
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Chemical References |
|
Topics |
- Anti-Retroviral Agents
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- Comorbidity
- HIV Infections
(complications, drug therapy, genetics)
- Humans
- Pharmacogenetics
|